Shaping the future of cardiac electrophysiology
Olva is developing a portable and reusable platform for cardiac ablation — making electrophysiology more accessible and sustainable.
Atrial fibrillation affects over 52 million people worldwide — a number expected to double by 2050.
EP requires heavy setup investments and high per-procedure costs.
Most patients depend on a few expert centers — creating disparities in care.
Single-use devices and complex logistics drive up environmental and economic costs.
7-figure investment
Bulky, complex infrastructure
Single-use catheters
with olva
Catheters reusable up to 20 times
An innovation that creates value for every stakeholder
Designed to support clinicians, improve patient outcomes, ease pressure on hospitals — and reduce environmental impact.
For hospitals
Be part of the future of electrophysiology
Olva is transforming cardiac EP. Investors, partners, talents — shape the future with us.
A solution the field has been waiting for
Founding Team
Chief Technology Officer
Rémi Dubois
Professor, engineer, and researcher at IHU Liryc, specialized in signal processing (25+ patents). He leads technical development.
Chief Executive Officer
Guillemette Duchateau
Manager & software developer. She leads strategic development and company growth.
Chief Medical Officer
Josselin Duchateau
Electrophysiologist at Bordeaux University Hospital and researcher at IHU Liryc. He ensures clinical relevance and impact.